What is the long-term trend for Syndax Pharmaceuticals's cash received from option exercises?

Over 4 years (2021 to 2025), Syndax Pharmaceuticals's cash received from option exercises has grown at a 17.6% compound annual growth rate (CAGR), from $6.34M to $12.14M.

Syndax Pharmaceuticals SNDX Cash received from option exercises

Cash received from option exercises at other companies

Rumble, Inc.RUM

$463-100.0%

Boston BeerSAM

$367K-17.7%

FMC CorporationFMC

$50K0.0%

NovaGold ResourcesNG

$0—

HNIHNI

$400K-96.8%

Q2 HoldingsQTWO

$0-100%

Other financials

Income statement

See full

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

See full

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

See full

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Valuation

See full

Market cap$1.77B+95.0%

Profitability

See full

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Returns & leverage

See full

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's cash received from option exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Syndax Pharmaceuticals's cash received from option exercises?: Syndax Pharmaceuticals (SNDX) reported cash received from option exercises of $7.46M in Q1 2026.
How has Syndax Pharmaceuticals's cash received from option exercises changed year-over-year?: Syndax Pharmaceuticals's cash received from option exercises increased by 1837.7% year-over-year, from $385K to $7.46M.
What is the long-term trend for Syndax Pharmaceuticals's cash received from option exercises?: Over 4 years (2021 to 2025), Syndax Pharmaceuticals's cash received from option exercises has grown at a 17.6% compound annual growth rate (CAGR), from $6.34M to $12.14M.